Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial

J Eur Acad Dermatol Venereol. 2016 Nov;30(11):e119-e121. doi: 10.1111/jdv.13391. Epub 2015 Sep 29.

Authors

C Hart¹, M Vogelhuber¹, C Hafner², M Landthaler², M Berneburg², S Haferkamp², W Herr¹, A Reichle³

Affiliations

¹ Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany.
² Department of Dermatology, University Hospital of Regensburg, Regensburg, Germany.
³ Department of Internal Medicine III, Haematology & Oncology, University Hospital of Regensburg, Regensburg, Germany. albrecht.reichle@ukr.de.

No abstract available

Publication types

Clinical Trial, Phase I
Letter

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Disease-Free Survival
Drug Administration Schedule
Humans
Melanoma / drug therapy*

Substances

Antineoplastic Agents

Associated data

GENBANK/NCT01614301